Shaily Engineering Plastics reports strong Q2 FY26 performance, healthcare surges

Shaily Engineering Plastics Limited (SEPL) announced strong operational and financial performance for Q2 FY26, with revenue growing by 34% year-on-year to INR257 crores. The healthcare segment was a primary driver, experiencing 163% growth to INR98.6 crores and doubling its contribution to the overall revenue mix to 38%. EBITDA doubled to INR82 crores, with margins expanding over 1,000 basis points to 31.8%. PAT increased by 134% year-on-year to INR51 crores, reaching a margin of 20%.

The company is actively expanding its healthcare capacity, aiming to increase pen production from 40m to 80m by the end of FY26, backed by an investment of INR125 crores. SEPL expects the healthcare segment to grow 30-40% annually for the next few years. The consumer and industrial segments also secured new projects, with the consumer electronics segment anticipating commercial supplies to commence in H2 FY26.

SEPL introduced the "Shaily Axiom Max" GLP-1 device, a fixed-dose pen, and secured four new projects across GLP-1 and other therapies. The company maintains a disciplined approach to capital, reflected in a debt-to-equity ratio of 0.3x and a fixed asset turnover ratio of 2x as of September 30, 2025.